Sight Sciences (SGHT) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Sight Sciences (SGHT) do?
Sight Sciences Inc (SGHT) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures surgical devices that restore natural fluid outflow to lower eye pressure in glaucoma patients. Develops handheld devices that restore natural drainage pathways to treat glaucoma and dry eye conditions. It is worth $590.25M on the market and sold $88.36M over the last year.
- Market cap
- $590.25M
- P/E ratio
- None (reported a loss)
- Annual sales
- $88.36M
- Sector
- Healthcare
- Industry
- Medical Devices
- Brief updated
- Nov 17, 2026
Brands and businesses behind SGHT
- OMNI: A handheld device used during glaucoma surgeries that generates revenue from sales of single-use units.
- TearCare: A wearable eyelid heating device that generates sales from both reusable controllers and disposable treatment pads.
- SION: A bladeless surgical instrument that earns revenue from disposable tool sales for micro-invasive trabeculotomy procedures.
SGHT’s flags, in plain English
Each flag is a number from Sight Sciences’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.
Stupid Cash
Can pay this year's bills 5 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Wide Gross Margin
Gross margin of 87.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Insiders Hold
Insiders own 34.9% of the company. The people who run the company own a meaningful slice of it, so they gain or lose along with other shareholders.
Burning Cash
Losing money, profit margin of -32.1%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
1 more green flag and 1 more risk note open with the free trial. Try it free for 7 days.
Questions about SGHT
How big is Sight Sciences?
Sight Sciences’ market cap is $590.25M: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $88.36M: what customers paid the company over the last year, before any costs.
What is SGHT’s P/E ratio?
SGHT has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with SGHT?
Medicare coverage determinations and local contractor pricing decisions directly dictate patient access and surgical utilization of canaloplasty procedures. That is one risk on Sight Sciences’ card. Its first risk flag is Burning Cash, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Sight Sciences’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. SGHT’s filings on SEC.gov. The Margin Monkey is research, not advice.
